Mounjaro and Menopause: What UK Women Need to Know (2026 update)
Key Takeaways (2026 Update)
Mounjaro can support weight loss in menopause
In one study, women on tirzepatide who were also using MHT/HRT lost more weight than those who weren't - but this is an association, not proof that MHT caused it
Muscle preservation requires protein + resistance training
NHS access is limited and evolving in the UK
Medication works best alongside lifestyle and behavioural support
Considering Mounjaro during menopause? This covers:
What the research currently tells us about Mounjaro and weight loss in menopause
Potential benefits and limitations
What we know about Mounjaro alongside MHT/HRT
Muscle and nutrition considerations
NHS access in the UK
What to think about before starting
Where you might be right now?
Considering starting → This blog
If you've worked through the practical side and you're asking what life looks like now → Life After GLP-1s: What Comes Next?
Mounjaro and Hormone Therapy - Why We’re Talking About This
Since this article was first published in September 2025, important new research has emerged on Mounjaro and menopause in the UK.
If you’re in the thick of menopause and feeling like your body has suddenly stopped playing by the rules, you’re not alone. Weight gain that won’t budge, hormone havoc and the sense that your GP doesn’t quite “get it” are daily struggles for so many women I work with.
And now there’s increasing buzz around Mounjaro® (tirzepatide), a drug originally developed for type 2 diabetes and now approved for weight management and the research specifically relevant to menopausal women has moved on considerably in the past few months.
What Exactly Is Mounjaro?
Mounjaro (tirzepatide) is a once-weekly injectable that targets both GLP-1 and GIP hormones, helping to regulate blood sugar and reduce appetite. This dual mechanism distinguishes it from GLP-1-only drugs like Wegovy and that’s one reason it’s attracting interest among midlife women navigating the metabolic slowdown of perimenopause and postmenopause.
Where Menopause & Mounjaro Intersect
As oestrogen levels fall, metabolism shifts, not because of personal failings, but due to hormonal change. This can mean more insulin resistance, increased abdominal fat and less responsiveness to habits that worked in the past.
Early research suggests tirzepatide may help reduce central adiposity (belly fat) across reproductive stages. While not a cure, it could become a supportive tool alongside nutrition, movement and lifestyle strategies.
A major post-hoc analysis of the SURMOUNT clinical trials (published in Obesity, 2025) confirmed that tirzepatide produces significant reductions in body weight and waist circumference across all reproductive stages - pre-, peri- and postmenopause - with 97–98% of women achieving at least 5% body weight loss versus 29–33% on placebo. Importantly, it also reduced waist-to-height ratio, a direct measure of central adiposity that is particularly pronounced during perimenopause.
Importantly, this benefit showed up across every reproductive stage - meaning tirzepatide isn't just effective before menopause, it holds up through peri- and postmenopause too.
That said, it's a supportive tool - not a standalone solution.
The 2026 Study: Mounjaro + MHT/HRT Together
A study published in The Lancet Obstetrics, Gynaecology, & Women's Health in January 2026 looked at postmenopausal women with overweight or obesity who'd been prescribed tirzepatide as part of their normal care.
Researchers, led by Mayo Clinic, pulled real-world health record data from 120 postmenopausal women who'd been on tirzepatide for at least a year. Women using hormone therapy were matched with non-users of a similar age, BMI and health background.
What they found:
By the end of the study period (around 18 months, on average), women using MHT had lost 19.2% of their starting body weight, compared with 14% for those not using hormone therapy - roughly a third more weight lost.
Nearly half of the MHT group (45%) lost 20% or more of their body weight, compared with 18% of the non-MHT group.
Women on MHT also showed bigger improvements in some markers of metabolic health, like blood pressure and cholesterol, though the study wasn't designed to prove that MHT was the reason why.
What we don't yet know:
This was an observational study, not a randomised controlled trial. It can show us a pattern - it can't prove that MHT caused the extra weight loss.
Women who choose to go on MHT may already differ in other ways: how bad their symptoms were, how much support they had, how well they were sleeping, how engaged they were with lifestyle changes. Any of these could explain part of what researchers saw.
The study didn't measure body composition directly, and it wasn't built to tell us anything about long-term safety, fractures or heart outcomes.
Bigger, better-designed trials are now being planned to test whether adding MHT really does boost the results of tirzepatide - and for which women it matters most.
For now: the pattern is interesting, and worth a conversation with your GP or menopause specialist. It isn't yet a reason to start MHT purely to lose more weight on Mounjaro.
What About Muscle Mass?
This is a question I hear constantly, and it's especially relevant for women in midlife when muscle is already under pressure from declining oestrogen.
A 2025 systematic review of randomised controlled trials (published in PMC) found that tirzepatide treatment is associated with reductions in fat mass while maintaining the relative preservation of lean mass, with indicators of muscle composition remaining stable or showing signs of improvement. PubMed Central
The nuance, though, is that this isn't automatic. Data from the SURMOUNT-1 body composition analysis shows that roughly 75% of weight lost with tirzepatide is fat mass and 25% is lean mass - a ratio similar to that seen with placebo, despite greater total weight reduction. What that means in practice: adequate protein intake and resistance training matter enormously, particularly for women over 40 whose muscle protein synthesis is already less responsive than it was in their 30s.
This is exactly the kind of gap a coach can help fill.
Losing weight and losing muscle aren't the same thing - and this is one part of the picture that's particularly important to think about during menopause.
Find out what can help protect your muscle while you're using a GLP-1 medication →
Can You Access Mounjaro Through the NHS in the UK?
The situation has shifted significantly since this post was first published in September 2025.
Where things stand in 2026:
The phased NHS rollout has continued - but access remains uneven. A British Medical Journal investigation in January 2026 found that one in five local areas still lacked a functional NHS pathway for Mounjaro, and these regional gaps are reportedly pushing some patients toward an unregulated black market for GLP-1 drugs - which carries serious safety risks. International Business Times
The biggest development is the 2026/27 GP contract. Announced in February 2026, a new government obesity strategy introduces financial incentives for GPs to move weight management from specialist clinics into local surgeries, with practices in England offered a bonus of up to £3,000 for actively managing patients on weight-loss injections such as tirzepatide - supported by £25 million in ring-fenced funding. International Business Times
By July 2026, an £85 million programme co-funded by the government and manufacturer Eli Lilly is expected to launch, testing additional access routes through community pharmacies and digital health platforms. International Business Times
It is possible to access Mounjaro through the NHS, but at the moment this is quite tightly controlled and depends on specific clinical criteria.
Current eligibility (Year 1 — 2025/26):
NHS prescribing through primary care still requires:
BMI of 40 or above (or 37.5 for South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean backgrounds)
Four or more weight-related comorbidities: type 2 diabetes, hypertension, cardiovascular disease, obstructive sleep apnoea, or dyslipidaemia
Engagement with mandatory wraparound care (nutritional and behavioural support)
Future phases are expected to widen access to those with BMI 35–39.9 plus comorbidities, but timelines vary significantly by ICB. If you don't yet meet the criteria, private access is available - though costs apply. Always check your local ICB for the latest position.
There's a lot to navigate when you're using Mounjaro during menopause - from how hormones interact with the medication to what happens when you come off it. The full GLP-1 and menopause guide brings it together in one place.
Where This Research Stands Now
The 2025 conference findings I mentioned earlier (from ENDO 2025) come from the same group of women described above - that data has now gone through peer review and been published in full, in the Lancet study above. I'm keeping this section short because the published paper is now the one to go by, rather than the earlier conference version
Safety & Interactions: What You Need to Know
Mounjaro, like any medication, can cause side effects - common ones include nausea, fatigue, or digestive changes.
1. Oral MHT, Oral Contraceptives, and Absorption
Tirzepatide slows down how quickly your stomach empties - especially just after you start it, and after each dose increase. This matters because it can affect how well your body absorbs other oral medications.
Oral contraceptives: this one is well established. In trials, tirzepatide cut peak absorption of a combined oral contraceptive pill by around 55–60%. Because of this, the guidance is clear: switch to a non-oral method (patch, ring, coil, implant or injection) or use a barrier method as well, for 4 weeks after starting tirzepatide and for 4 weeks after every dose increase.
Oral MHT/HRT: this is where I want to be more precise than I was originally. There's no direct study showing that oral HRT/MHT becomes less effective when you're also on tirzepatide. But because the same "slower digestion" mechanism could plausibly affect how oral oestrogen and progestogen are absorbed, many clinicians choose to be cautious - preferring non-oral MHT (patches, gels, sprays, or a hormonal coil for womb protection) for women starting tirzepatide, particularly where getting the dose right really matters, such as for endometrial protection.
To be clear: this is a sensible precaution based on how the drug works, not a proven interaction. It's not an official British Menopause Society rule specific to tirzepatide. Whether oral or non-oral MHT is right for you should be a conversation with your GP or menopause specialist, factoring in your symptoms, your clotting risk, migraines, and what you'd rather be using day to day.
2. Holistic Support: Muscle, Protein and Lifestyle
Clinical commentary underscores that while these drugs can be impactful, they are not magic bullets. Lifestyle changes remain crucial and there are concerns about long-term effectiveness and resource strain on primary care The Guardian+1.
Given what we now know about lean mass loss, nutritional support is more important than ever alongside tirzepatide. Appetite suppression can make it easy to under-eat protein without realising - which matters enormously for women in midlife trying to maintain muscle, metabolism and energy.
Many women find that while medications like Mounjaro can support weight loss, they don’t address the wider picture of what’s happening in midlife - from energy and muscle loss to emotional load and changing stress tolerance. This is often where personalised support becomes important, helping you translate medical treatment into something sustainable in real life.
If you’re using Mounjaro but want to understand the wider menopause picture too, Menopause Essentials provides a structured foundation across nutrition, movement, sleep, stress and sustainable behaviour change.
This isn’t just about weight - it’s about understanding what’s changing
For many women, conversations about medications like Mounjaro come at a point where something already feels off.
Weight changing in ways that don’t make sense.
Energy feeling harder to sustain.
Your body responding differently to things that used to work.
So it’s natural to look for solutions.
But as you’ve seen, this isn’t a simple decision.
Mounjaro works by affecting appetite, blood sugar and digestion - including slowing how quickly food and medication move through your system.
Which means it can also affect how other medications are absorbed, including some forms of MHT/HRT.
This is why it’s not just about whether something works -
but how it fits into the bigger picture of your body, your hormones and your overall health.
Why This Isn't a Simple Decision
Weight changing in ways that don't make sense, energy that's harder to sustain, a body that's stopped responding the way it used to - it's natural to want a fix.
But knowing why something is happening doesn't automatically tell you what to do about it, or how to apply it consistently. In menopause, sleep, stress, blood sugar and hormonal shifts all interact, which is why a single fix rarely resolves everything on its own. Mounjaro may be part of the answer to weight change, but sustainable health still has to work within the life you're actually living - your schedule, your energy, everyone else's needs alongside your own.
This is what I call the Menopause Action Gap™ - the gap between understanding what's happening in your body and being able to respond to it in a way that actually works in real life. My approach, the MHC Method™, is built to close that gap.
Where to Go From Here
A useful first step is stepping back from "what should I take?" and asking instead: what is my body actually asking for right now?
Start with the free Perimenopause Blueprint → It'll help you see the connection between your hormones, metabolism and energy - with or without medication in the picture.
If you'd rather talk it through, a Menopause Clarity Call is a free, unhurried conversation about your options - whether you're weighing up Mounjaro, already using it, or leaning toward a non-medication route.
Book your free Menopause Clarity Call →
Not sure yet whether coaching's the right fit? Five signs it might be worth a conversation →
This article reflects current research and evidence-informed practice. I work within the UKIHCA scope as a health coach and do not provide medical advice.
References & Evidence
Castaneda R et al. The role of menopause hormone therapy in modulating tirzepatide-associated weight loss in postmenopausal women with overweight or obesity: a retrospective cohort study. The Lancet Obstetrics, Gynaecology, & Women's Health. January 22, 2026. Link
Mayo Clinic News Network - New study links combination of hormone therapy and tirzepatide to greater weight loss after menopause. January 22, 2026.
Tchang BG et al. Body weight reduction in women treated with tirzepatide by reproductive stage: a post hoc analysis from the SURMOUNT program. Obesity (Silver Spring). 2025;33:851–860. PMC12015656
Systematic review: Effects of tirzepatide on skeletal muscle mass in adults. PMC12394919, 2025. Link
NHS England - 2026/27 GP contract obesity strategy. Announced February 23, 2026
NHS England - Tirzepatide in primary care wraparound care guidance. Link
King's College London / BJGP editorial: Tirzepatide and the NHS - are we creating a two-tier obesity treatment system? January 2026. ScienceDaily
NHS England - Tirzepatide (Mounjaro) weight management eligibility, March 2025 NHS England
NHS Cheshire & Merseyside - phased rollout criteria, June 2025 onward NHS Cheshire and Merseyside
Lincolnshire ICB - eligibility breakdown and ethnic adjustments Lincolnshire ICB
Endocrine Society (ENDO 2025) - Mounjaro + MHT enhanced weight loss Endocrinegastroenterologyadvisor.com
British Menopause Society - interaction with oral progesterone and HRT route guidance British Menopause Society
Data on tirzepatide’s impact on oral contraceptive absorption healthed.com.auPubMedReproductive Health Access Project
GP commentary and NHS rollout context The Guardian+1
Coaching Benefits & Client Experiences
The Importance of Health Coaching for Holistic GLP-1 and Weight Management Support
Explains how Health Coaches play a key role in supporting clients on GLP-1 drugs by guiding them toward sustainable lifestyle changes that improve overall health and address the root causes of metabolic imbalance.GLP-1 Nutrition Support
Discusses the necessity to have nutritional meal plans aligning with GLP-1 medications and clients' goals, digestive symptom relief strategies, and menopause and hormone health support.
